TY - JOUR
T1 - Rebound in community antibiotic consumption after the observed decrease during the COVID-19 pandemic, EU/EEA, 2022
AU - Ventura-Gabarró, Cèlia
AU - Leung, Vivian H.
AU - Vlahović-Palčevski, Vera
AU - Machowska, Anna
AU - Monnet, Dominique L.
AU - Högberg, Liselotte Diaz
AU - ESAC-Net study group
A2 - Strauss, Reinhild
A2 - Catteau, Lucy
A2 - Stoikov, Ivan
A2 - Payerl-Pal, Marina
A2 - Kyriakidou, Isavella
A2 - Prokeš, Michal
A2 - Attauabi, Majda
A2 - Sepp, Janne
A2 - Sarvikivi, Emmi
A2 - Hider-Mlynarz, Karima
A2 - Schweickert, Birgitta
A2 - Mellou, Kassiani
A2 - Matuz, Maria
A2 - Halldórsdóttir, Anna Margrét
A2 - Gurpinar, Emre Umut
A2 - Fortinguerra, Filomena
A2 - Rutkovska, Ieva
A2 - Valinteliene, Rolanda
A2 - Saleh, Stéphanie
A2 - Zarb, Peter
A2 - Baltink, Jan
A2 - Blix, Hege Salvesen
A2 - Olcza-Pieńkowska, Anna
A2 - Silva, Ana
A2 - Popescu, Gabriel Adrian
A2 - Tesař, Tomáš
A2 - Subelj, Maja
A2 - López-Navas, Antonio
A2 - Obeid, Ragda
N1 - List of national organisations participating in ESAC-Net:
https://www.ecdc.europa.eu/en/about-us/partnerships-and-networks/disease-and-laboratory-networks/esac-net
Publisher Copyright:
© 2023 European Centre for Disease Prevention and Control (ECDC). All rights reserved.
PY - 2023/11/16
Y1 - 2023/11/16
N2 - We observed a rebound in consumption of antibacterials for systemic use (ATC J01) in the community sector in the European Union/European Economic Area during 2021 and 2022, after an observed decrease between 2019 and 2020. The rates in 2022 returned to preCOVID-19-pandemic levels and were exceeded in 13 countries. Although these patterns could partly be a result of changes in disease transmission during the study period, it could also reflect a lost opportunity to strengthen and reinforce prudent antibiotic use.
AB - We observed a rebound in consumption of antibacterials for systemic use (ATC J01) in the community sector in the European Union/European Economic Area during 2021 and 2022, after an observed decrease between 2019 and 2020. The rates in 2022 returned to preCOVID-19-pandemic levels and were exceeded in 13 countries. Although these patterns could partly be a result of changes in disease transmission during the study period, it could also reflect a lost opportunity to strengthen and reinforce prudent antibiotic use.
UR - http://www.scopus.com/inward/record.url?scp=85177977375&partnerID=8YFLogxK
U2 - 10.2807/1560-7917.ES.2023.28.46.2300604
DO - 10.2807/1560-7917.ES.2023.28.46.2300604
M3 - Article
C2 - 37971660
AN - SCOPUS:85177977375
SN - 1025-496X
VL - 28
JO - EUROSURVEILLANCE
JF - EUROSURVEILLANCE
IS - 46
M1 - 2300604
ER -
